Euro Foscan study to boost biolitec's PDT (photodynamic therapy) drug
This article was originally published in Clinica
German photodynamic therapy company biolitec last week successfully ended a five-year-plus study of its Foscan PDT light-activated drug for head and neck tumours, which was required by the European Medicines Evaluation Agency (EMEA). Jena-based biolitec says the therapy should now be able to retain its approval. Furthermore, completion of the study will lead to "considerably greater" market penetration for the photodynamic therapy (PDT) drug, for which the company is now also preparing to embark on approval negotiations with the US FDA.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.